

INDEX

A

- Activity-based diubiquitin probes
 - ABPs 12, 223
- Adaptational behavioral variations 70
- Adrenal medullary hypertrophy 27
- Allosteric relationship, allostery 234
- Alternative splicing 5, 163
- 7-Aminoactinomycin D (7-AAD) 176, 185, 189
- Anaerobic respiration 72
- Antibody
 - arrays 95
 - microarray (forward capture) 211
 - transfection efficiencies 6, 202
- Anti-cancer drug response 101–112, 114
- Anti-multiple myeloma 54
- Antisense oligos 86, 98
- ANXA1 25
- ANXA2 25
- ANXA7 23–32
- ANXA7-GTPase 23–32
- Apparent diffusion coefficient (ADC) 71, 73, 78
- Array staining 216–218
- ATP-competitive inhibitors 234, 237–238, 240–241
- AutoCAD (computer-aid-design program
 - from Autodesk) 177
- Autophagy-lysosome system 49, 50, 55–57
- Autophagosomes 50, 52, 56
- Autophagy
 - chaperone-mediated autophagy 7, 50
 - macroautophagy 7, 50
 - microautophagy 7, 50

B

- Barcoded libraries for multiplex sequencing 157–158
- Bayesian models, Bayesian network inference 106
- Biofunctions 91, 95
- Bioinformatics 193, 219
- Biological robustness 104
- Biomarkers 2, 8, 12, 38, 39, 42, 45, 62, 63, 87, 209–221
 - proteins 209–221
 - validation 209–221
- Biospecimens 39–41, 46, 184
- Blood–brain barrier 73
- Blood flow 63, 69, 70, 73, 76, 174

- Body fluid 7, 211, 213, 215–216
- Bone Marrow Mononuclear Cells (BMMC),
 - cryopreservation 185

C

- Ca²⁺-activated GTPase protein 28
- Ca⁽²⁺⁾/GTP-dependent secretion and exocytosis 25
- Calcium homeostasis 28
- Cancer
 - biology 2, 8, 171
 - gene networks 2–8
 - genes for drug discovery 111–113
 - systems biology 2, 13, 101, 210
- The Cancer Genome Atlas (TCGA) 73–76, 168
- Canonical pathways 91, 95
- Carboxyfluorescein diacetate, succinimidyl ester
 - (CFSE) 176, 184–187, 189
- Cell/organism-based phenotypic assays 104
- Cell penetrating peptide (CPP) 202, 207
- Cell printing 172
- Cell survival and proliferation 88
- Cellular density 63, 69, 70, 72, 77
- Cellular homeostasis 49
- Cellularity 74, 78
- Cellular thermal shift assay (CETSA) 6, 13, 14, 16, 17
- Centrality metrics 3, 102, 103, 105, 112
- Chemical ligation 223, 230, 231
- Chemical synthesis 223, 224, 226, 228, 229, 231
- Chemoproteomics 6, 11–14, 16–21
- Chemoresistance 54
- Chemotherapeutic agent 72
- Chloroquine 51, 52
- Chromaffin cell hyperplasia 27
- Chromatin-immunoprecipitation (ChIP),
 - ChIP-qPCR 134
- Chromatography 2, 6, 38, 39, 41, 42, 206, 224
- Clinical imaging 4, 62–70, 72–74, 77–79
- Clinical outcomes 32, 54, 65, 78, 172
- CLIP-Seq
 - HITS-CLIP 198
 - PAR-CLIP 198
- Coefficients of variation (CVs) 44
- Combinatorial complexity 114
- Combinatorial drug pharmacology 103, 104

Combinatorial space.....114
 Compensatory pathways.....104
 Computational methods
 ASprofile163
 computational methods to detect exon-skipping
 events.....4, 5, 163–169
 computational predictions167, 193, 195–199
 DiffSplice163
 DSGseq.....163
 Computed tomography (CT)3, 65, 67
 Confocal microscopy184, 202
 Connectivity maps.....91, 95
 Contrast enhancing region (CE).....68, 70, 74, 77, 78
 Correlation of epigenetic marks with exon-skipping
 events.....169
 CRISPR121, 123, 124, 127, 133, 138
 Cas technology4
 Cas9 nuclease120
 Cas9-mediated mutagenesis128
 chimeric guide RNA (gRNA)121
 design tool.....127, 128, 132
 gRNA paring.....132
 gRNA133–134
 hPSC lines.....132
 iCRISPR system
 generation of epitope tag knockin hPSC
 lines.....127, 133
 generation of knockin epitope-tagged hPSCs
 using132–137
 genome editing platform121, 123, 138
 workflow for iCRISPR-mediated knockin in
 hPSCs.....124
 Cross-sectional imaging66, 79
 Cytoplasmic delivery of proteins201–207
 Cytoskeleton proteins202, 203

D

d-2-hydroxyglutarate (D-2HG).....38
 Darwinian
 dynamics.....3, 62, 68, 69, 79
 Database5, 6, 12, 42, 43, 46, 94, 97,
 166, 194, 197–198, 209
 De novo exon-skipping.....5, 164
 Dehydrogenase (IDH).....38
 Delivery
 dsDNA plasmids138
 gRNAs.....138
 ssDNA.....138
 Design of Donor ssDNA.....4, 133–134
 Deubiquitinating enzymes (DUBs).....49–57
 The DUB active-site cysteine.....8, 223
 DUB profiling223
 Diagnostic imaging methods.....65–67, 69–74, 78
 Disease recurrence25, 31, 63, 71, 78

Diubiquitin probe.....223, 224, 226, 228, 229, 231
 DNA contaminated dRNA (DNA/dRNA)148
 DNase treated DNA/dRNA148, 150
 Double strand break (DSB).....120, 121
 Drug
 combination.....3, 102, 104, 106, 108, 114
 DARTS6, 14–16
 discovery programs6, 8, 11–14, 16–21,
 102, 103, 106, 111–114, 171
 drug-dependent mechanisms.....103
 drug targets identification.....103–108
 drug-target interaction networks102
 efficacy.....104, 109, 114
 metabolism62
 resistance3, 4, 106–107, 120, 125, 172, 173
 screening.....106, 114
 targets identification103–108
 DSBs123, 124
 Duplex-specific nuclease (DSN)142, 144–147,
 154–158, 160

E

Ecology.....4, 63–65, 68–70, 73, 76, 78, 79
 Ecosystem.....3, 4, 63, 69, 70, 79
 Electroporation.....129, 204–207
 Endoplasmic reticulum.....28
 Endoribonuclease233
 Enhancement patterns.....66
 Epidermal growth factor receptor (EGFR).....62, 71
 Epigenetics
 factors163–169
 regulated exon-skipping.....163–169
 Epitope tags.....4, 120, 121, 123, 132–138
 ER stress.....233
 Evolutionary biology78
 Exon-skipping5, 163–169
 Expression profiling.....76, 88, 90, 93–97, 171, 194
 Extra cellular matrix (ECM)172, 174, 184

F

Fail-safe mechanisms.....104
 Fc-Cre as a cargo protein202, 205
 Feedback loops104, 106
 Ficoll density gradient separation.....183–185
 Filtering predictions with multi-targeting195
 Finer-grained characterization76
 Flow cytometry.....131, 176, 185–187,
 189, 202, 205–206
 Fluid-attenuated inversion recovery (FLAIR).....71, 73,
 74, 77, 78
 Fluorescent reporters120, 123
 fluorescent-tagged hPSC lines.....4, 121
 Formalin-fixed paraffin-embedded (FFPE)
 RNA141, 148, 152–154, 160

Forward chemical genetics.....103
 Fragmented
 large RNA (FLgRNA >200nt)..... 142, 145
 FTRNA..... 142, 151–153, 155, 160, 161
 Fumarate hydratase (FH)38
 Functional annotation tools198
 Fusion proteins 19, 120, 125, 133

G

Gadolinium contrast enhanced T1 sequence
 (T1Gd) 71, 74, 76–78
 Gas chromatography 6, 38
 Gene expression in situ.....164
 Gene targeting..... 121, 138, 195
 Genetic predisposition to disease.....28
 Genome browser 37, 38, 63, 73, 74, 88,
 89, 114, 119–121, 123, 132, 133, 138, 165, 166, 168,
 169, 196, 198, 209
 genome-editing platform in hPSCs.....121
 signature of drug(s) response106
 GDSC database.....111
 genotypic profiling.....106
 Glioblastoma (GBM).....24, 25, 65, 68,
 70–73, 75–78
 Global evolutionary dynamics63
 Glucose metabolism72
 Graph-based exon-skipping scanner (GESS).....5, 164–168
 gRNA-expressing plasmids127

H

Habitat
 imaging.....72–74, 76
 suitability index.....69
 Hemorrhage65
 Hercules II fusion DNA polymerase 122, 126,
 128, 130, 132, 135, 137
 HIF-1 α 8, 95, 97
 High-energy collisional dissociation (HDC)40
 High-resolution/accurate-mass (HR/AM)40
 HIV-TAT_{47–57} peptide.....207
 Homeostasis28, 51, 54, 57, 104
 Homologous recombination 4, 119, 120, 137
 Homology directed repair (HDR).....121
 Human metabolome database42
 Human OSB cell line hFOB.....174
 Human pluripotent stem cells (hPSCs)..... 4, 119–126,
 128–138
 Humanized bone microenvironment.....173
 Hydrophilic compounds39
 Hydrophilic Interaction Chromatography
 (HILIC)39
 Hydrophobic compounds39
 Hydroxychloroquine51, 52
 Hypoxia68, 74, 77, 79, 84

I

IC5018, 19, 108, 237–241
 Imaging-defined tissue heterogeneity.....65
 Immune
 immunofluorescence120
 immunoprecipitation (IP).....4, 86, 120, 136–137
 immunostaining.....217–218
 immunotherapy52, 63
 response 25, 27, 68, 72
 In silico modeling102
 Individualized medicine76
 Induced pluripotent stem cells (hiPSCs).....119
 Inference of drug–target networks..... 3, 108–109
 Ingenuity pathway analysis (IPA) 89, 91
 Inhibitors 6, 18–20, 51–55, 57, 106–107,
 122, 124, 130, 131, 212–216, 234, 235, 237–241
 Inositol-requiring enzyme 1 alpha (IRE1 α) 233–241
 Input-output relationships.....2
 IntAct protein interaction network.....112
 Integrative clinical proteomics.....210
 Internal ribosome entry site (IRES)125
 Inter-observer variability66
 Interstitial edema..... 63, 66, 69,
 70, 73, 78
 Intracellular calcium chelator BAPTA29
 Intra-class correlation coefficients (ICCs)45
 Intratumoral
 Darwinian dynamics.....69
 evolutionary dynamics 63, 78
 habitats70–72
 heterogeneity4, 62, 69, 70, 72
 imaging.....78
 molecular heterogeneity.....69
 population dynamics.....63
 proteogenomic heterogeneity.....65
 textural variations66
 Invasion and metastasis 31, 32, 84, 87, 97, 173
 Ionomycin.....29
 IP₃-receptors.....28
 IRE1 α
 enzymatic assays233–241
 Isobaric chemical tags.....18
 Isocitrate dehydrogenase (IDH).....38

K

K-factor clustering technique69
 Kinase Inhibiting RNase Attenuators
 (KIRAs) 234, 237, 239, 241
 Kinobeads..... 6, 18–20
 Knockdown 8, 84–91, 93–98
 Knockin
 alleles 119–121, 123, 126
 reporter allele120
 Knockout mouse.....27

L

Label-free quantitation (LFQ)..... 19, 20
 Landscape ecology..... 4, 63–65, 68–70, 76
 Library Quantification and Multiplexing with
 Barcodes..... 157–158
 Limited proteolysis coupled with single reaction monitoring
 (LiP-SRM)..... 15, 16
 Lineage-specific knockin fluorescent reporters..... 120
 Linkage specificity..... 223
 Lipidomics..... 6, 39–40
 Lipofectamine 3000..... 122, 129, 137
 Liquid-chromatography 2, 39, 41
 Loss of heterozygosity (LOH) 24

M

Macro/micro-scale tumor properties 65
 Macroscopic spatial resolution..... 66
 Magnetic resonance imaging (MRI) 63, 65, 70
 mass spectrometry 2, 6, 7, 11–13, 17, 19,
 38–39, 41, 42, 211, 229
 MaxQuant program..... 20
 Medical imaging..... 66, 70–72, 79
 Metabolights 43
 Metabolomics
 biomarkers 37–39, 41, 42, 46
 profiling 40
 Methylation..... 84, 169
 Microarray
 data analysis..... 218–220
 printing..... 212, 214–216
 Microcosm..... 69
 Microenvironment
 microenvironment-mimicking framework..... 172
 Microfluidics
 device fabrication..... 176–178
 microfluidic stricture..... 5
 microfluidic-based perfusion culture..... 172
 MicroRNA (miRNA)..... 88, 90, 141, 154, 161, 193–199
 arrays 90
 expression 88–93, 194, 196
 knock-down or knock-in 194
 miRanda 195–196, 198, 199
 miRBase version of the miRanda algorithm..... 194, 199
 miRNA–gene interactions..... 198
 miRNA–mRNA pairs..... 194, 198, 199
 miRNA–mRNA target prediction..... 198
 miRNA–mRNA targets..... 197
 miRNA–target interactions..... 197
 mirRecords, target prediction 193–199
 targets 5, 194–199
 MimiRNA..... 196, 198
 The mimiRNA website 196, 198
 Mineralized bone..... 173

Mixture of isoforms (MISO) model..... 5, 165–167
 Molecular
 feature signatures 106–107
 chaperones 50
 determinants 84–91, 93–98
 heterogeneity 3, 62, 66, 69
 Mono and multicellular spheroids 172
 MRI..... 3, 66, 68–70, 72–74, 77, 78
 MRI-defined habitats..... 69, 73
 MS total useful signal (MSTUS) 45
 Multi-drug phenotypic profiles 105, 108
 Multi-feature signature of drug response..... 106–107
 Multiparametric characteristics 72, 74
 Multiple myeloma (MM)..... 5, 20, 52–54, 57, 171–189
 Multiple myeloma cells (MMC) 54, 176
 Multiple myeloma niche..... 173
 Multiplex RNA-seq..... 147–148
 Multi-targeting..... 5, 194–196
 Multivariate analysis of variance (MANOVA)..... 112

N

Necrosis..... 8, 66, 70–74, 77, 83, 84
 Network
 analysis..... 102–104, 114
 centrality..... 111–113
 dynamics..... 105
 inference 103, 104, 106
 node centrality metrics..... 102
 nodes 102, 105, 109
 oriented approaches..... 3, 101–112, 114
 pharmacology 102, 103
 stability 102
 topological node properties..... 103
 topology..... 3, 104
 vulnerability..... 2, 3, 109–111
 NF-kB 84
 Nfragmented degraded RNA (dRNA)..... 148
 Niches..... 3, 69, 70, 79, 172, 173
 NOD/SCID-GAMMA (NSG) mice..... 173
 Node centrality 3, 102, 112, 113
 Node strength in drug–gene network..... 113
 Non-enhancing region (NE) 70, 74, 77, 78
 Non-homologous end joining (NHEJ) pathway 120
 Non-model based inference of drug–target
 networks 108–110
 Normalization 44–45, 157
 Nuclear Magnetic Resonance (NMR) 6, 38–39, 41, 224
 Nutrient-poor environments 57

O

Oncology 62, 66, 68, 75–79
 Oncometabolites..... 37–46
 Organelles 50, 51
 Ossified tissue construction 181–183

Osteoblast (OSB)-derived 3D tissue scaffold..... 174, 176
 Osteoblast-derived tissue scaffold.....5
 The Otsu algorithm.....74

P

Paring
 design of CRISPR gRNAs..... 133–134
 Patient compliance63
 Patient-specific diagnostic screening platforms172
 Patrolling monocytes (PMo)98
 PCL fiber mesh 178, 184, 186
 Perfusion
 culture device5, 172, 174, 176,
 178–183, 186, 189
 Personalized cancer therapy.....72
 Personalized medicine 171–173, 210
 Phenotype-based drug profiling 105, 108
 PicTar 195, 196
 Polar metabolites39
 Polydimethylsiloxane (PDMS)
 layer 178, 180
 layer modification180
 plugs 179, 183, 188
 fabrication.....179
 Poly ϵ -caprolactone (PCL)..... 175, 178, 184, 186
 Poly(A+) RNA141
 Positron emission tomography (PET).....66
 Predator-like dynamics.....72
 Profecction206
 Prognosis 26, 31, 54, 66, 72, 78, 87–88
 Prognostic biomarkers71
 Programmable site-specific nucleases120
 Promoter array.....84
 Prostatic intraepithelia neoplasms (PIN).....25
 Protein
 degradation inhibitors.....51, 57
 delivery201–207
 expression profiles..... 88, 93–97
 homeostasis..... 49, 54, 57
 interaction network.....112–114
 kinase..... 18–20, 122
 PLIMSTEX.....17
 microarrays 7, 209–221
 transfection202, 205–206
 transfection rates.....205–206
 Protein transduction domain (PTD).....201
 Proteogenomics 65, 72, 79
 Proteome 7, 11, 37, 84–91, 93–98, 209
 Proteomics..... 2, 6, 7, 11–18, 20, 21, 32, 209–211
 Proteosomal inhibitors
 bortezomib52, 57
 carfilzomib.....53
 delanzomib53
 ixazomib53

marizomib53
 oprozomib53
 Proteotoxic stress49, 51
 Protospacer adjacent motif (PAM).....121
 Pulmonary colonization..... 86, 98

Q

qPCR Assay for rRNA Reduction157
 qRT-PCR..... 89, 93, 138, 157
 Quantitative
 clinical imaging..... 62–70, 72–74, 77–79
 multiscale predictive models2
 radio-genomics70
 and reproducible metrics.....66

R

Radiomics.....4, 66–68, 72–74, 79
 Radio-pathomic maps77, 78
 Radio-pathomics70
 Radiosensitivity72
 Reads Per Kb per Million reads (RPKM)145
 Region of interest (ROI)74
 Regional phenotypic adaptations.....68
 Response Evaluation Criteria in Solid Tumors
 (RECIST)66
 Retention times (RTs)39, 41
 Reverse
 chemical genetics103
 RCPM.....209–221
 RP chromatography.....39
 Ribosomal RNA sequences4
 RIN value (RNA integrity number)159
 RNA-induced silencing complex (RISC).....193
 RNase8, 129, 143, 144, 150–154,
 156, 157, 176, 233, 234, 238–241
 RNaseH.....154
 RNaseOut153
 RNA-sequencing (RNA-seq)..... 2, 4, 5, 68,
 141–145, 147–161, 164–167, 169
 libraries 145, 147–148, 151

S

Satellite images..... 3, 64, 65,
 69, 70, 76
 SC1 REW22 Cre indicator cell..... 203, 205, 206
 Schematics of protein and promoter fusion knockin
 strategies126
 Self-renewal.....119
 Sequencing platforms 4, 142, 158, 161
 illumina platforms
 HiS161
 HiSeq 4, 142, 158
 MiSeq.....4, 142
 NextSeq.....4, 142

SERCA-pump ATPase	29
Serine/threonine kinase IRE1 α	233–241
Serum/plasma/other body fluid source plate preparations	215–216
Serum-centric approach	211
Severe combined immunodeficient (SCID) mouse	173
shRNA	88, 89
Signaling networks	211
Signaling pathway	26, 32, 97
SILAC-based proteomic analysis	20
Single reaction monitoring (SRM)	15, 16
Single stranded DNAs (ssDNA)	4, 121, 123, 124, 127, 128, 133–135, 138, 155, 156, 160, 161
SiRNA	86–88
Small RNA (smRNA <200nt)	145, 148, 150
Small molecule inhibitors	54, 234
SOC	29
Software	
Marker Lynx	41
MAVEN	41
PRIME	41
XCMS	41
Somatic evolution	68
Spatial heterogeneity	63, 70
Spatially explicit habitats	76–78
Species map	4, 65
Splicing	2, 5, 8, 88, 126, 163–169
SPROX	15
Stability of proteins from rates of oxidation (SPROX)	6, 13–18
Standard of care (SOC)	62, 65, 79
Standard operating procedures (SOPs)	40
StarBase	198
Static 3D tumor models	172
tore-operated calcium channel (SOC)	26, 28, 29
Subomic technologies	2
Succinate dehydrogenase (SDH)	38
SUPREX technique	18
Surrogate markers	78
Synergy and antagonism	114
SyproRuby stain	218, 219, 221
Systems-oriented drug design	114
T	
T1 post-gadolinium contrast (T1Gd)	71, 73, 74, 76–78
TarBase	198
Target	
genes	5, 123, 125, 126, 196–198
TargetScan algorithm	194–197, 199
Thapsigargin	28, 29
Therapeutic target	31–32, 50, 54, 88
Thermal shift assay (TSA)	16
Three-dimensional (3D)	
biomaterial scaffold	172
cellular architecture	172
microfluidic tissue culture device	174–176, 181–183, 188
multiparametric tumor cluster map	71
multiple myeloma tissue model construction	181–186
ossified tissue construct	181–184
TIPE homology (TH) domain	84
Tissue dissociation	176
Tissue engineering platforms	171–189
Tophat splicing aware alignment	165
Topological properties	102–104
Total ion current (TIC)	45
Toxicity	53, 55, 62
Transcriptome	
transcriptome profiling	141
Transcription	
TALENs	120
Treatment resistance	72, 74, 78, 79
Triple quadrupole mass spectrometry	41
Triple-negative breast cancer (TNBC)	55, 105
TruSeq libraries	144, 157
Tumor	
heterogeneity	3, 63
microenvironment	171–189
microenvironment	5
progression	51, 63, 65, 88, 173
progression	8, 89
TSG	8, 24, 28, 32, 89
Tumor necrosis factor- α -inducible protein 8 (TNFAIP8)	8, 84–91, 93–98
Two-dimensional (2D) culture	171
U	
Ubiquitin	
chain	223
C-terminal hydrolases (UCHs)	54
UPS	7, 49–51, 53–57
Unfolded protein response (UPR)	7, 8, 233
Unfragmented degraded RNA (dRNA)	155
3'UTR	
3'UTR databases	197
V	
Validation of rRNA sequence reduction in TruSeq Libraries	157
vibrational centrality	3, 105, 109–113
W	
Web-based data repository, METLIN	42
Well plate-based perfusion culture device fabrication	178–183
X	
X-box protein 1 (XBP1)	8, 233, 235, 238, 240, 241
Z	
Zinc finger nucleases (ZFNs)	120